HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J9356 | Trastuzumab and Hyaluronidase-oysk | Herceptin hylecta | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2019 | Jul 1, 2019 | In Use | ||
J9302 | Ofatumumab | Arzerra | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2009 | Jan 1, 2011 | In Use | ||
Q5113 | Trastuzumab-pkrb | Herzuma | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2018 | Jul 1, 2019 | In Use | ||
Q5116 | Trastuzumab-qyyp | Trazimera | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2020 | Oct 1, 2019 | In Use | ||
J9269 | Tagraxofusp-erzs | Elzonris | 10mcg | Immunotherapy | Recombinant Fusion Protein | IL3/CD123 | No | 2018 | Oct 1, 2019 | In Use | ||
NA | Cedazuridine and Decitabine | Inqovi | 100mg, 35mg | Chemotherapy | Antimetabolite | Pyrimidine Analog + CDA Inhibitor | Yes | 2020 | In Use | |||
NA | Entrectinib | Rozlytrek | 100mg, 200mg | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Yes | 2019 | In Use | |||
NA | Fedratinib Hydrochloride | Inrebic | 100mg | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Yes | 2019 | In Use | |||
Pacritinib | Vonjo | 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Yes | 2022 | In Use | ||||
J9198 | Gemcitabine HCl | Infugem | 100mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2018 | Jul 1, 2020 | In Use | ||
C9082 | Dostarlimab-gxly | Jemperli | 100mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
NA | Avapritinib | Ayvakit | 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
J9052 | Carmustine (Accord) | Carmustine | 100mg | Chemotherapy | Alkylating Agent | Nitrosurea | No | 2022 | Dec 7, 2023 | In Use | ||
NA | Pralsetinib | Gavreto | 100mg | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Yes | 2020 | In Use | |||
J0885 | Epoetin Alfa | Epogen, Procrit | 1000 units | Ancillary Therapy | Erythropoiesis-Stimulating Agent | No | 1989 | Jan 1, 2006 | In Use | |||
J9050 | Carmustine | Bicnu | 100 mg | Chemotherapy | Alkylating Agent | Nitrosourea | No | 1977 | Jan 1, 1984 | In Use | ||
C9421 | Cyclophosphamide | Cyclophosphamide lyophilized | 100 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
J9070 | Cyclophosphamide | Cyclophosphamide | 100 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1984 | Apr 17, 2024 | No Longer Used | |
S0088 | Imatinib mesylate | Gleevec | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2001 | Jan 1, 2002 | In Use | ||
S0116 | Bevacizumab | Avastin | 100 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jul 1, 2004 | Jun 30, 2006 | No Longer Used | |
NA | idelalisib | Zydelig | 100 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
NA | Vandetanib | Caprelsa | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Yes | 2011 | In Use | |||
NA | Nintedanib | Ofev | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Yes | 2014 | In Use | |||
NA | Niraparib | Zejula | 100 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | Abemaciclib | Verzenio | 100 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.